ESTRO 2024 - Abstract Book

S2723

Interdisciplinary - Global health

ESTRO 2024

231

Poster Discussion

Hypofractionated Radiotherapy for Prostate Cancer: Preliminary Results from the HYPOAFRICA Study

Abba Mallum 1 , Adedayo O Joseph 2 , Solomon Kibudde 3 , Twalib A Ngoma 4 , Azeezat Ajose 2 , Emmanuel Lugina 5 , Jumaa D Kisukari 5 , Kavuma Awusi 3 , Samuel O Adeneye 2 , Thokozani Mkhize 1 , Adewumi Alabi 2 , Ibrahim El Hamamsi 2 , Mark A Mseti 5 , Precious Akowe 2 , Andrej Studen 6 , Heng Li 7 , Joerg Lehmann 8 , M. Saiful Huq 9 , Stephen Avery 10 , Elizabeth Olatunji 11 , Katy M Graef 12 , Saloni Patel 11 , William Swanson 13 , Wilfred Ngwa 7 , Luca Incrocci 14 1 Inkosi Albert Luthuli Central Hospital, Radiation Oncology, Durban, South Africa. 2 NSIA-LUTH Cancer Center, Radiation Oncology, Lagos, Nigeria. 3 Uganda Cancer Institute, Radiation Oncology, Kampala, Uganda. 4 Muhimbili University of Health and Allied Sciences, Clinical Oncology, Dar Es Salaam, Tanzania, United Republic of. 5 Ocean Road Cancer Institute, Radiation Oncology, Dar Es Salaam, Tanzania, United Republic of. 6 University of Ljubljana, Medical Physics, Ljubljana, Slovenia. 7 Johns Hopkins University, Radiation Oncology, Bethesda, USA. 8 Calvary Mater Newcastle, Radiation Oncology, Newcastle, Australia. 9 University of Pittsburg Medical Center Hillman Cancer Center, Radiation Oncology, Pittsburgh, USA. 10 University of Pennsylvania, Radiation Oncology, Philadelphia, USA. 11 Johns Hopkins University, School of Medicine, Baltimore, USA. 12 BIO Ventures for Global Health, -, Seattle, USA. 13 Weill Cornell Medicine, Radiation Oncology, New York City, USA. 14 Erasmus Medical Center, Radiation Oncology, Rotterdam, Netherlands

Purpose/Objective:

Several randomized studies conducted in Europe and the USA have demonstrated that hypofractionated radiotherapy (HFRT) for prostate cancer (PCa) is non-inferior to conventional radiotherapy in terms of toxicity and treatment outcomes. The rising number of PCa patients in sub-Saharan Africa, especially in the context of resource limitations, warrants the adoption of evidence-based approaches that enhance treatment accessibility. HFRT substantially increases access to radiotherapy by reducing overall treatment cost and duration for patients, while also reducing the burden on limited personnel and infrastructural resources. HypoAfrica is a multi-center phase II study launched in 2021 in Nigeria, South Africa, and Tanzania to investigate the feasibility of applying moderate HFRT for the treatment of PCa in the African context.

Material/Methods:

Patients with histologically-confirmed localized non-metastatic PCa are enrolled to receive an HFRT total dose of either 60Gy (low- and intermediate-risk PCa) or 62Gy (high-risk PCa) delivered in 20 fractions. Gastrointestinal (GI) and genitourinary (GU) toxicities are assessed using RTOG-EORTC and CTCAE criteria before the start and upon completion of radiotherapy and at 3-, 12-, and 24-months post completion of radiotherapy.

Results:

Of the 163 patients enrolled to date, 132 (mean age: 70 years, range 50-82 years) have finished HFRT and 92 of those have completed their 3-month post-radiotherapy assessment. Fifty-two percent received 60Gy (n=69) and 48% (n=63) received 62Gy. Radiotherapy was administered either via IMRT (n=81, 61%) or VMAT (n=51, 39%)